Cargando…
Exploring the comparative cardiovascular death benefits of sodium–glucose cotransporter 2 inhibitors in type 2 diabetes: a frequentist and Bayesian network meta-analysis-based scoring
BACKGROUND AND AIMS: Cardiovascular death (CV death) is the most objective component of the primary or secondary endpoint in cardiovascular outcome trials (CVOTs) conducted with sodium–glucose cotransporter 2 inhibitors (SGLT-2is). CV death is often incorporated into primary composite outcomes. It i...
Autores principales: | Ghosal, Samit, Sinha, Binayak |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353048/ https://www.ncbi.nlm.nih.gov/pubmed/37469980 http://dx.doi.org/10.3389/fendo.2023.1168755 |
Ejemplares similares
-
A Meta-Analysis of the Effect of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic Parameters in Patients With Polycystic Ovary Syndrome
por: Sinha, Binayak, et al.
Publicado: (2022) -
Meta‐analysis of the effects of sodium glucose cotransporter 2 inhibitors in non‐alcoholic fatty liver disease patients with type 2 diabetes
por: Sinha, Binayak, et al.
Publicado: (2020) -
Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) Reduce Hospitalization for Heart Failure Only and Have No Effect on Atherosclerotic Cardiovascular Events: A Meta-Analysis
por: Sinha, Binayak, et al.
Publicado: (2019) -
Finerenone in type 2 diabetes and renal outcomes: A random-effects model meta-analysis
por: Ghosal, Samit, et al.
Publicado: (2023) -
Heterogeneity in cardiovascular death or hospitalization for heart failure benefits with flozins is linked to weight
por: Ghosal, Samit, et al.
Publicado: (2023)